Provided by Tiger Fintech (Singapore) Pte. Ltd.

Summit Hotel Properties

4.07
+0.01000.25%
Pre-market: 3.51-0.5600-13.76%06:28 EDT
Volume:1.15M
Turnover:4.63M
Market Cap:453.32M
PE:18.48
High:4.11
Open:4.11
Low:3.94
Close:4.06
Loading ...

Should Value Investors Buy Summit Hotel Properties (INN) Stock?

Zacks
·
26 Feb

Summit Hotel Properties Inc (INN) Q4 2024 Earnings Call Highlights: Strong AFFO Growth and ...

GuruFocus.com
·
26 Feb

Q4 2024 Summit Hotel Properties Inc Earnings Call

Thomson Reuters StreetEvents
·
26 Feb

Summit Hotel Properties Reports Strong 2024 Results

TIPRANKS
·
26 Feb

Stock Track | Summit Hotel Properties Plunges 8.36% in Pre-market on Disappointing Q4 Results and Outlook

Stock Track
·
25 Feb

Summit Hotel Properties Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Summit Hotel Properties (INN) Q4 FFO and Revenues Beat Estimates

Zacks
·
25 Feb

Summit Hotel Properties: Q4 Earnings Snapshot

Associated Press Finance
·
25 Feb

Summit Hotel Properties Q4 AFFO per common share $0.20, Inline, Sales $172.93M Beat $172.08M Estimate

Benzinga
·
25 Feb

BRIEF-Summit Hotel Properties Q4 Adjusted FFO Per Share USD 0.2

Reuters
·
25 Feb

Summit Hotel Properties Q4 Revpar USD 117.21

THOMSON REUTERS
·
25 Feb

Summit Hotel Properties Inc Outlook FY25 Adjusted Ffo per Share of Common Stock and Common Units $0.90- $1.00

THOMSON REUTERS
·
25 Feb

Summit Hotel Properties Inc FY2025 Ffo Shr View $0.97 -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Summit Hotel Properties Q4 Net Income USD 680 Thousand

THOMSON REUTERS
·
25 Feb

Actinogen reports busy 6 months as development of Xanamem molecule ramps up

The Market Herald
·
24 Feb

Summit Hotel Properties Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
22 Feb

Park Hotels & Resorts (PK) Q4 FFO Miss Estimates

Zacks
·
20 Feb

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

GlobeNewswire
·
19 Feb

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

GlobeNewswire
·
18 Feb

Summit Hotel Properties (INN): Among the Best Hotel Stocks to Buy According to Analysts

Insider Monkey
·
17 Feb